Back to search resultsSummaryRMgm-676
|
||||||||
*RMgm-676| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene tagging |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 22139844 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | Not applicable |
| Other information parent line | |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Montagna, G.N.; Matuschewski, K. |
| Name Group/Department | Parasitology Unit |
| Name Institute | Max Planck Institute for Infection Biology |
| City | Berlin |
| Country | Germany |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-676 |
| Principal name | HSP20-mCherry |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | mCherry signals barely detected in all blood stages |
| Gametocyte/Gamete | Not different from wild type |
| Fertilization and ookinete | mCherry-HSP20 abundantly expressed in ookinetes |
| Oocyst | mCherry-HSP20 abundantly expressed in oocysts |
| Sporozoite | mCherry-HSP20 abundantly expressed in sporozoites (see 'Additional remarks phenotype') |
| Liver stage | See 'Additional remarks phenotype' |
| Additional remarks phenotype | Mutant/mutation Phenotype analyses of mutants lacking expression of HSP20 (RMgm-672, RMgm-675) provide evidence that HSP20 is involved in ookinete and sporozoite motility. Phenotype Additional information |
Tagged: Mutant parasite with a tagged gene| top of page | |||||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_0714300 | ||||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0816500 | ||||||||||||||||||||||||||
| Gene product | small heat shock protein HSP20, putative | ||||||||||||||||||||||||||
| Gene product: Alternative name | HSP20 | ||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||||
| Name of the tag | mCherry | ||||||||||||||||||||||||||
| Details of tagging | C-terminal | ||||||||||||||||||||||||||
| Additional remarks: tagging | |||||||||||||||||||||||||||
| Commercial source of tag-antibodies | |||||||||||||||||||||||||||
| Type of plasmid/construct | Plasmid single cross-over | ||||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||||
| Restriction sites to linearize plasmid | PacI | ||||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||||
| Additional remarks genetic modification | For fusion of the red fluorescent protein mCherry to the PbHSP20 5’UTR and ORF, a 1493 bp fragment was cloned into SacII-SpeI sites of the BD3+mCherry vector. A PCR fragment corresponding to the PbHSP20 5’UTR and ORF was amplified with primers 5’UTR Hsp20 SacII (5´-TCCCCGCGGGGAGTTTAAAATTATTGCTAGTTC-3´) and Hsp20 rvSpeI (5’- CGGACTAGTCCGTGCTTCGTTTATTTCTACTTTATGC-3’) and cloned into the SacII-SpeI sites of the BD3D+mCherry vector, resulting in the HSP20 mCherry fusion construct. This targeting plasmid was linearized with PacI. | ||||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||